Skip to main content
. Author manuscript; available in PMC: 2020 Feb 1.
Published in final edited form as: CNS Drugs. 2019 Feb;33(2):99–106. doi: 10.1007/s40263-018-0598-1

Table 1.

Anti-Amyloid Compounds in Secondary Prevention Trials for AD

Drug Mechanism of Action Phase
Solanezumab Passive immunization III
Crenezumab Passive immunization III
Gantenerumab Passive immunization III
Aducanumab Passive immunization III
BAN2401 Passive immunization II
CAD106 Active immunization II
Verubacestat BACE Inhibition Abandoned
Atabacestat BACE Inhibition Abandoned
Lanabacestat BACE Inhibition Abandoned
Elenbacestat BACE Inhibition II
CNP520 BACE Inhibition II
*

BACE – Beta amyloid cleaving enzyme